

# Clopidogrel (hydrogen sulfate)

Catalog No: tcsc1882



## Available Sizes

**Size:** 100mg

**Size:** 500mg



## Specifications

**CAS No:**

120202-66-6

**Formula:**

$C_{16}H_{18}ClNO_6S_2$

**Pathway:**

GPCR/G Protein

**Target:**

P2Y Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 46.7$  mg/mL (111.22 mM)

**Alternative Names:**

(S)-(+)-Clopidogrel bisulfate;(S)-(+)-Clopidogrel hydrogen sulfate

**Observed Molecular Weight:**


419.9

## Product Description

S-(+)-Clopidogrel Hydrogen Sulfate is the S enantiomer of clopidogrel and a P2Y<sub>12</sub> receptor inhibitor.

Target: P2Y Receptor

Clopidogrel is an effective antiplatelet agent useful for the treatment of ischemic cerebrovascular, cardiac, and peripheral arterial disease. Clopidogrel abolishes the inhibitory P2Y<sub>12</sub> receptor-mediated ADP effects on prostaglandin E<sub>1</sub>-stimulated, cAMP-dependent phosphorylation of VASP without affecting epinephrine, thrombin, and thromboxane signaling. VASP phosphorylation is known to be closely correlated with the inhibition of platelet and fibrinogen receptor (glycoprotein IIb/IIIa) activation. Therefore, inhibition of the platelet P2Y<sub>12</sub> ADP receptor and its intracellular signaling, including decreased VASP phosphorylation, is suggested as a molecular mechanism of clopidogrel action [1]. Clopidogrel ingestion reduced the thrombus volume significantly (p < 0.05).  
Clinical indications: Acute coronary syndrome; Peripheral vascular disease; Thromboembolism



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!